Sofia Birgersson

Sofia Birgersson

Auto-generated profile, based on publicly available information

Sofia Birgersson

Department of Pharmacology, Unit of Pharmacokinetics and Drug Metabolism, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2026 in Current Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Open access
PDF file
ARAlexis Rugamba
Alexis Rugamba
PMPernilla Malmgren
Pernilla Malmgren
EBEmile NA BIENVENU
Emile NA BIENVENU
SBSofia Birgersson
Sofia Birgersson
Introduction: Introduction: Differences in genotypes encoding drug-metabolizing enzymes can lead to variability in both drug response and toxicity. These genotypes vary across geographical regions and ethnic groups, especially in African populations. In general, African populations are underrepresented in clinical trials. This study aimed to determine the allele frequencies of CYP2C8, CYP2C9, CYP2C19, and CYP1B1 in the Rwandan population; to explore potential clinical impact on toxicity of the CYP2C8*2 variant on paclitaxel metabolism and the need for genotype-based dosing using a population pharmacokinetic model. Methods: Genotyping was performed on DNA extracted from blood samples obtained from 82 Rwandan patients. Paclitaxel plasma concentrations for the different CYP2C8 genotypes were simulated based on available in vitro metabolism data and a population pharmacokinetic model. Toxicity was assessed as time above plasma concentration thresholds (>0.05 and 0.1 μM), and genotype-based dose regimens were simulated. Results: The frequencies of the polymorphic alleles in the Rwandan population were 21%, 0.6%, 1.8%, 24%, and 26% for CYP2C8*2, CYP2C9*2, CYP2C19*3, CYP2C19*17, and CYP1B1*3, respectively. Simulations showed that CYP2C8*2 carriers spent approximately 1.7-fold and 1.9-fold longer above paclitaxel toxicity thresholds of 0.05 and 0.1 μM, respectively, than wild-type individuals. A dose of 100 mg/m² in CYP2C8*2 carriers produced exposure comparable to 175 mg/m² in wild-type individuals. Discussion: The relatively high prevalence of CYP2C8*2 in the Rwandan population suggests potential clinical relevance for paclitaxel treatment. Conclusion: CYP2C8*2 may influence paclitaxel exposure and support genotype-guided dose reduction to improve treatment safety.

20 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ARAlexis Rugamba
Alexis Rugamba
NJNattapon Jaisupa
Nattapon Jaisupa
SBSofia Birgersson
Sofia Birgersson
Background: Cancer, particularly breast cancer, poses a significant global health challenge, driving an increasing demand for chemotherapy. Paclitaxel, a widely used chemotherapeutic agent, is primarily metabolized by the cytochrome P450 enzymes CYP2C8 and CYP3A4, generating metabolites such as 6α-hydroxypaclitaxel and p-3-hydroxypaclitaxel. Although these metabolites lack pharmacological activity, paclitaxel metabolism influences both efficacy and toxicity, necessitating the need for accurate monitoring of both drug and metabolite levels.,Objectives: To develop and validate a robust, selective, rapid and sensitive LC-MS/MS method for the simultaneous quantification of paclitaxel, 6α-hydroxypaclitaxel, and p-3-hydroxypaclitaxel in human plasma.,Methods: Chromatographic and mass spectrometric conditions were optimized and validated according to FDA guidelines.,Results: A rapid LC-MS/MS method was developed with a total run time of 5 minutes. Lower limits of quantification (LLOQ) were 2.5 nM for paclitaxel and 5 nM for both metabolites. The method demonstrated excellent linearity, precision, accuracy, and sensitivity, with calibration standards and quality control samples meeting acceptance criteria. The method was highly selective, with no significant interference from plasma components or the co-administered drug, trastuzumab.,Conclusion: A robust and sensitive LC-MS/MS method for the quantification of paclitaxel and its two major metabolites in human plasma was successfully developed and validated. The improved sensitivity, particularly the lower LLOQ for paclitaxel, represents an advantage over previous analytical approaches. This assay is suitable for pharmacokinetic studies and may support individualized chemotherapy optimization, particularly in underrepresented populations such as those in sub-Saharan Africa.